Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHL1922 vs Pulmozyme PK/Safety in Healthy Subjects
NCT03586076Phase 1Completed
- Sponsor
- Eden Biologics, Inc.
- Start
- Jan 2018
- Primary completion
- Jun 2018
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dornase alfa in cystic fibrosis (CF) (2 arms), sponsored by Eden Biologics, Inc. Primary endpoints: Maximum Plasma Concentration up to 21 days, Area Under the Curve to Last Timepoint up to 21 days and 2 more. Started Jan 2018; status: completed.
02
Drugs
dornase alfa
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03586076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03586076.